September 2023

record medical interest in obesity

Oprah & Ozempic; inevitable GLP-1 plateaus; record medical interest in obesity; compounded med controversy; pharma-based economic disruption.

Hello everyone, I hope you are well. We have some quite interesting news pieces this week, including reporting on Eli Lilly’s lawsuits against compounding pharmacies; record-setting interest in physicians applying to take the the American Board of Obesity Medicine (ABOM) exam; and, Oprah and a panel of obesity specialists diving into the GLP-1 topic. Also, […]

Oprah & Ozempic; inevitable GLP-1 plateaus; record medical interest in obesity; compounded med controversy; pharma-based economic disruption. Read More »

Over 70 companies in the obesity medications race

Over 70 companies in the obesity medications race; a new business model for weight management; obesity in youths as a public health emergency; a 40% reduction in blood cancers after bariatric surgery

Hello everyone, I hope you are enjoying this weekend, one where — at least in much of the US Northeast — the weather is feeling like the first crisp glimpses of autumn [though I note that, if you were exposed to Hurricane Lee, it may be wet and windy, and with the inconvenience of power

Over 70 companies in the obesity medications race; a new business model for weight management; obesity in youths as a public health emergency; a 40% reduction in blood cancers after bariatric surgery Read More »

Bariatric surgery

The future – or not – of bariatric surgery; access disparities in GLP-1 medications (and taking second jobs to pay for them); cost per avoided cardiovascular death; and, are bacteria the new Ozempic?

Hello everyone, Welcome to September; I hope you are well on this long Labour Day weekend in North America. [And I will note, Labour Day is celebrated in many more places around the world than just the US and Canada, though it is more commonly celebrated on May 1st and alternately or also known as

The future – or not – of bariatric surgery; access disparities in GLP-1 medications (and taking second jobs to pay for them); cost per avoided cardiovascular death; and, are bacteria the new Ozempic? Read More »

More on GLP-1s: adherence, complications, impact on desire; nextgen weight management; and, Lisa Marie Presley’s tragic death

Hello everyone, my very best to you this weekend, and I hope you are staying cool in this current heat wave in North America [if you are located here]. Hydrate, hydrate, hydrate! Overall, this has been a quiet mid-summer week, apart from any of you who celebrated the national day of France this week, July

More on GLP-1s: adherence, complications, impact on desire; nextgen weight management; and, Lisa Marie Presley’s tragic death Read More »

Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow - not shrink - along with rising GLP-1 adoption.

Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow – not shrink – along with rising GLP-1 adoption.

Hello everyone, I hope you are quite well on this beautiful weekend (at least, here in the US Northeast). Virtually everyone I know, including yours truly and family, are out & about enjoying it. In this edition of our twenty30 newsletter, we continue to see keen media attention on GLP-1s, helping facilitate public fascination and concurrent

Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow – not shrink – along with rising GLP-1 adoption. Read More »

Scroll to Top
Skip to content